Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
Patientenergebnisse nach Buprenorphin-Behandlung bei Opioidkonsumstörung: retrospektive Analyse des Einflusses von Patienten- und Verschreibermerkmalen in Massachusetts, USA
Addiction · 2025-01 · 120 (1) · 152-163
DOI: 10.1111/add.16684 ↗Auf einen Blick
Eine retrospektive Analyse von 37 955 Patient:innen untersuchte Ergebnisse nach Beginn einer Buprenorphin-Behandlung. Soziodemografische und Verschreibermerkmale waren mit schlechteren Outcomes verbunden.
Fragestellung
Welchen Einfluss haben Patienten- und Verschreibermerkmale auf Ergebnisse nach Beginn einer Buprenorphin-Behandlung bei OUD?
Methode
Retrospektive Beobachtungsstudie mit Daten aus dem Public Health Data Warehouse in Massachusetts; multilevel models; Beginn 2015 bis 2019; 12-monatiges Follow-up.
Ergebnisse
59,7 % hatten eine schlechte Medikamentenkontinuität, 57,4 % brachen die Behandlung ab und 10,3 % erlitten eine Opioidüberdosierung; 1,1 % hatten eine fatale Überdosierung. Schwarze und hispanische Patient:innen sowie Medicaid-Versicherte hatten schlechtere Outcomes.
Schlussfolgerung der Autor:innen
Patienten- und Verschreibermerkmale scheinen mit den Ergebnissen nach Buprenorphin-Behandlung assoziiert zu sein. Besonders Rasse/Ethnizität, Versicherung und Verschreibermerkmale waren mit Unterschieden verbunden.
Kernaussagen
- Schlechte Medikamentenkontinuität: 59,7 %
- Behandlungsabbruch: 57,4 %; Überdosierung: 10,3 %
- Schlechtere Outcomes bei Schwarzen, Hispanics und Medicaid-Versicherten
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift Addiction, online erschienen am 13.10.2024. Verfasst von Gary J Young und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment, Buprenorphine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background and Aims Opioid use disorder (OUD) is treatable with buprenorphine/naloxone (buprenorphine), but many patients discontinue treatment prematurely. The aim of this study was to assess the influence of patient‐ and prescriber‐level characteristics relative to several patient outcomes following the initiation of buprenorphine treatment for OUD.
Design
This was a retrospective observational investigation. We used the Public Health Data Warehouse from the Massachusetts Department of Public Health to construct a sample of patients who initiated buprenorphine treatment between 2015 and 2019. We attributed each patient to a prescriber based on information from prescription claims. We used multilevel models to assess the influence of patient‐ and prescriber‐level characteristics on each outcome.
Setting
Massachusetts, USA.
Participants
The study cohort comprised 37 955 unique patients and 2146 prescribers. Among patients, 64.6% were male, 52.6% were under the age of 35 and 82.2% were White, non‐Hispanic. For insurance coverage, 72.1% had Medicaid.
Measurements
The outcome measures were poor medication continuity, treatment discontinuation and opioid overdose, all assessed within a 12‐month follow‐up period that began with a focal prescription for buprenorphine. Each patient had a single follow‐up period. Poor medication continuity was defined as medication gaps totaling more than 7 days during the initial 180 days of buprenorphine treatment and treatment discontinuation was defined as having a medication gap for 2 consecutive months within the 12‐month follow‐up period.
Findings
The patient‐level rates for poor medication continuity, treatment discontinuation and opioid overdose were 59.7% [95% confidence interval (CI) = 59.2–60.2], 57.4% (95% CI = 56.9–57.9) and 10.3% (95% CI = 10.0–10.6), respectively, with 1.1% (95% CI = 1.0–1.2) experiencing a fatal opioid overdose. At the patient level, after adjustment for covariates, adverse outcomes were associated with race/ethnicity as both Black, non‐Hispanic and Hispanic patients had worse outcomes than did White, non‐Hispanic patients (Black, non‐Hispanic ‐‐ poor continuity: 1.50, 95% CI = 1.34–1.68; discontinuation: 1.44, 95% CI = 1.30–1.60; Hispanic ‐‐ poor continuity: 1.21, 95% CI = 1.12–1.31; discontinuation: 1.38, 95% CI = 1.28–1.48). Patients with insurance coverage through Medicaid also had worse outcomes than those with commercial insurance (poor continuity: 1.18, 95% CI = 1.11–1.26; discontinuation: 1.09, 95% CI = 1.03–1.16; overdose: 1.98, 95% CI = 1.75–2.23). Pre‐treatment mental health conditions and other types of chronic illness were also associated with worse outcomes (History of mental health conditions ‐‐ poor continuity: 1.11, 95% CI = 1.06–1.17; discontinuation: 1.05, CI = 1.01–1.10; overdose: 1.47, 95% CI = 1.36–1.60; Chronic health conditions ‐‐ poor continuity: 1.15, 95% CI = 1.05–1.27; discontinuation: 1.15, 95% CI = 1.05–1.26; overdose: 1.83, 95% CI = 1.60–2.10; History of substance use disorder other than for opioids ‐‐ poor continuity: 1.54, 95% CI = 1.46–1.62; discontinuation: 1.54, 95% CI = 1.47–1.62; overdose: 1.93, 95% CI = 1.80–2.07). At the prescriber level, after adjustments for covariates, adverse outcomes were associated with clinical training, as primary care physicians had higher rates of adverse outcomes than psychiatrists (poor continuity: 1.12, 95% CI = 1.02–1.23; discontinuation: 1.04, 95% CI = 1.01–1.09). A larger prescriber panel size, based on number of patients being prescribed buprenorphine, was also associated with higher rates of adverse outcomes (poor continuity: 1.36, 95% CI = 1.27–1.46; discontinuation: 1.21, 95% CI = 1.14–1.28; overdose: 1.10, 95% CI = 1.01–1.19). Between 9% and 15% of the variation among patients for the outcomes was accounted for at the prescriber level.
Conclusions
Patient‐ and prescriber‐level characteristics appear to be associated with patient outcomes following buprenorphine treatment for opioid use disorder. In particular, patients' race/ethnicity and insurance coverage appear to be associated with substantial disparities in outcomes, and prescriber characteristics appear to be most closely associated with medication continuity during early treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Health Policy and Healthcare Research, Northeastern University, Boston, MA, USA.
- Bouve College of Health Sciences, Northeastern University, Boston, MA, USA.
- D'Amore-McKim School of Business, Northeastern University, Boston, MA, USA.
- Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA, USA.
- Department of Information Systems and Operations Management, Warrington College of Business and Department of Pharmaceutical Outcomes and Policy, School of Pharmacy, University of Florida, Gainesville, FL, USA.
- Prescription Monitoring Program, Massachusetts Department of Public Health, Boston, MA, USA.
ORCID-Profile: Md Noor-E-Alam
Förderung
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Young, G. J., Zhu, T., Hasan, M. M., Alinezhad, F., Young, L. D., & Noor-E-Alam, M. (2025). Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA. Addiction, 120(1), 152-163. https://doi.org/10.1111/add.16684
Vancouver
Young GJ, Zhu T, Hasan MM, Alinezhad F, Young LD, Noor-E-Alam M. Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA. Addiction. 2025;120(1):152-163. doi:10.1111/add.16684
BibTeX
@article{Young2025,
author = {Young, Gary J and Zhu, Tianjie and Hasan, Md Mahmudul and Alinezhad, Farbod and Young, Leonard D and Noor-E-Alam, Md},
title = {Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA},
journal = {Addiction},
year = {2025},
volume = {120},
number = {1},
pages = {152--163},
doi = {10.1111/add.16684}
}
EUVIMED